Showing results (1551-1560 of 1,651) with videos related to

Sort By:
Pageof 166
Atherosclerosis|February 25, 2025
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trialJie Lin, Yuan Ji, Gaopin Wang, et al.
Natural Product Research|April 15, 2026
Evaluation of antimycobacterial, antibacterial, and anticancer activities of new nodulisporacid derivatives isolated from endophytic fungus Hypoxylon pulicicidum using in silico studiesPierre Roger Koliye, Achille Nouga Bissoue, Baruch Ateba Amana, et al.
Journal of Sports Sciences|August 20, 2023
Associations between changes of smartphone pedometer-assessed step counts and levels of obesity-related breast cancer biomarkers in non-cancer women: A population-based observational studyXunying Zhao, Xiaohua Liu, Xueyao Wu, et al.
Frontiers in Pharmacology|February 15, 2021
Mitochondrial Iron Overload-Mediated Inhibition of Nrf2-HO-1/GPX4 Assisted ALI-Induced NephrotoxicityHui-Fang Deng, Lan-Xin Yue, Ning-Ning Wang, et al.
Virology|April 7, 2017
Extensive diversity of coronaviruses in bats from ChinaXian-Dan Lin, Wen Wang, Zong-Yu Hao, et al.
Nature Communications|February 4, 2026
Engineering thin 3D Li-composite foil negative electrodes with high mechanical toughnessYu-Hao Wang, Shuang-Jie Tan, Chao-Hui Zhang, et al.
One Health (Amsterdam, Netherlands)|March 6, 2023
Geographical distribution of Ixodes persulcatus and associated pathogens: Analysis of integrated data from a China field survey and global published dataShan-Shan Wang, Jin-Yue Liu, Bao-Yu Wang, et al.
Medicine|February 6, 2015
LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational studyNan Hu, Ge Wang, Yu-Hao Wu, et al.
Zhonghua Nan Ke Xue = National Journal of Andrology|August 8, 2025
[Application of China-made Toumai Robot in laparoscopic radical prostatectomy]Zhi-Feng Wei, Yu-Hao Chen, Ze-Peng Zhu, et al.
Atherosclerosis|June 21, 2025
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trialChunli Shao, Shu Zhang, Zhifeng Cheng, et al.
Pageof 166